Neoplasms by Site Terminated Phase 3 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01009593Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)Treatment